JWA
NNVC icon

JFS Wealth Advisors’s NanoViricides NNVC Stock Holding History

JFS Wealth Advisors’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$1K – 509
2018
Q3 		$1K Buy
+200
New +$1.54K ﹤0.01% 509

Other funds holding NNVC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PTB
Pioneer Trust Bank Salem, Oregon $441M AUM 21.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

JFS Wealth Advisors's NNVC Position: Q4 2018 in Review

JFS Wealth Advisors sold out of NanoViricides (NNVC) in Q4 2018, closing a stake of 200 shares — an estimated $1K sold.

JFS Wealth Advisors first reported a position in NNVC in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 40 funds tracked by Wall St. Rank hold NNVC as of Q4 2018.

  • JFS Wealth Advisors reported no remaining NanoViricides position as of Q4 2018 after selling out during the quarter.
  • JFS Wealth Advisors sold 200 NanoViricides shares in Q4 2018, an estimated $1K.
  • JFS Wealth Advisors first reported a position in NanoViricides in Q3 2018 and held it in 1 quarter.
  • JFS Wealth Advisors's NanoViricides position peaked at $1K in Q3 2018.
  • 40 funds tracked by Wall St. Rank held NanoViricides as of Q4 2018.

Based on JFS Wealth Advisors's 13F filing for Q4 2018, filed 28 Jan 2019.